paclitaxel has been researched along with Opportunistic Infections in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hamann, MT; Kasanah, N; Shilabin, AG; Wedge, DE | 1 |
| Burstein, HJ; Najita, J; Tolaney, SM; Winer, EP | 1 |
| Agbalika, F; Bouché, C; Kerob, D; Lafaurie, M; Lebbé, C; Lévy, A; Nassar, D; Schartz, NE | 1 |
| Fietkau, R; Iro, H; Klautke, G; Kuwert, T; Lell, M; Linke, R; Semrau, S; Uder, M; Waldfahrer, F | 1 |
| Havemann, K; Merte, H; Pfab, R; Pflüger, KH; Reckzeh, B; Wolf, M | 1 |
1 review(s) available for paclitaxel and Opportunistic Infections
| Article | Year |
|---|---|
Kaposi's sarcoma after long-acting steroids: time until remission and drug washout.
Topics: Anti-Inflammatory Agents; Bleomycin; Blood Glucose; CD4 Lymphocyte Count; Humans; Immunoglobulin G; Immunosuppression Therapy; Insulin; Interferon-alpha; Male; Middle Aged; Opportunistic Infections; Paclitaxel; Sarcoma, Kaposi; Skin Ulcer; Triamcinolone Acetonide | 2010 |
2 trial(s) available for paclitaxel and Opportunistic Infections
| Article | Year |
|---|---|
Lymphopenia associated with adjuvant anthracycline/ taxane regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; CD4 Lymphocyte Count; Cohort Studies; Cyclophosphamide; Doxorubicin; Female; Humans; Incidence; Lymphopenia; Middle Aged; Opportunistic Infections; Paclitaxel | 2008 |
Severe lymphocytopenia and interstitial pneumonia in patients treated with paclitaxel and simultaneous radiotherapy for non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Drug Administration Schedule; Flow Cytometry; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Count; Lymphopenia; Middle Aged; Opportunistic Infections; Paclitaxel; Radiotherapy, Adjuvant | 1996 |
2 other study(ies) available for paclitaxel and Opportunistic Infections
| Article | Year |
|---|---|
Lysosome and HER3 (ErbB3) selective anticancer agent kahalalide F: semisynthetic modifications and antifungal lead-exploration studies.
Topics: Antifungal Agents; Antineoplastic Agents; Antiparasitic Agents; Cell Line, Tumor; Depsipeptides; Drug Screening Assays, Antitumor; Fusarium; Humans; Lysosomes; Microbiological Techniques; Mycobacterium tuberculosis; Opportunistic Infections; Parasitic Sensitivity Tests; Receptor, ErbB-3; Structure-Activity Relationship | 2007 |
Feasibility, toxicity, and efficacy of short induction chemotherapy of docetaxel plus cisplatin or carboplatin (TP) followed by concurrent chemoradio-therapy for organ preservation in advanced cancer of the hypopharynx, larynx, and base of tongue. Early r
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Disease Progression; Docetaxel; Feasibility Studies; Female; Follow-Up Studies; Humans; Hypopharyngeal Neoplasms; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Kaplan-Meier Estimate; Laryngeal Neoplasms; Leukopenia; Lymphatic Metastasis; Male; Neoadjuvant Therapy; Neoplasm Staging; Opportunistic Infections; Paclitaxel; Positron-Emission Tomography; Radiodermatitis; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Salvage Therapy; Taxoids; Thrombocytopenia; Tomography, X-Ray Computed; Tongue Neoplasms; Treatment Outcome | 2011 |